Allergan Presents Data at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego

DUBLIN, Feb. 16, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that its data will be featured during the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, February 16-20, 2018.

The meeting will be held at the San Diego Convention Center and the scheduled times (noted in local Pacific Time) for the Allergan presentations, titles and authors are as follows:

Podium Presentations

Once-Daily Oral Sarecycline 1.5 mg/kg/day for Moderate to Severe Acne Vulgaris: Pooled Data From Two Phase 3 Pivotal Studies

• Authors: Leon H. Kircik, Neal D. Bhatia, Edward Lain, Angela Moore, Joel Schlessinger, Linda Stein-Gold, Stephen K. Tyring, Carsten Schmitz, Terry I. Boodhoo, David R. Berk, Alexandre Kaoukhov
• Saturday, 2/17, 9:24 - 9:36 AM, Room 6D

Serial Photographic Assessment of Effect of Oxymetazoline Cream 1.0% on Persistent Facial Erythema of Rosacea

• Authors: Lawrence F. Eichenfield, James Q. Del Rosso, Jerry K.L. Tan, Julie Harper, Leon H. Kircik, Adelaide A. Hebert, Hilary E. Baldwin, Linda Stein-Gold, Guy F. Webster, Alexandre Kaoukhov, Nancy Alvandi
• Saturday, 2/17, 10:00 ? 10:12 AM, Room 6D

Oral Poster Presentations

Topical Oxymetazoline Hydrochloride 1.0% Effectively Reduces Persistent Facial Erythema of Rosacea on Day 1

• Authors: Emil A. Tanghetti, Jeffrey S. Dover, David J. Goldberg, Sunil S. Dhawan, Yiyong Fu, David Berk, Gurpreet Ahluwalia, Nancy Alvandi
• Saturday, 2/17, 9:35 ? 9:40 AM, e-Poster Presentation Center 2

Poster Presentations

OnabotulinumtoxinA for Treatment of Moderate to Severe Horizontal Frontalis Lines and Glabellar Lines From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study

• Authors: Dayan S, Ogilvie P, Rivkin; Yoelin S, Ferrusi I
• Available for online viewing during program

Simultaneous Treatment of Moderate to Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines With OnabotulinumtoxinA From the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes From a Phase 3 Double-Blind Study

• Authors: Dayan S, Ogilvie P, Rivkin; Yoelin S, Ferrusi I
• Available for online viewing during program

Efficacy, Safety, and Patient-Reported Outcomes in Male Subjects Treated With OnabotulinumtoxinA for Improvement of Moderate to Severe Horizontal Forehead Lines

• Authors: Keaney T, Cavallini M, Leys C, Rossi A, Mao C, Garcia J, Gallagher C, Shumate G
• Available for online viewing during program

In Vitro Inflammatory and Immune Response to Uncrosslinked Hyaluronic Acid (HA) and HA Fillers

• Authors: Hee C, Nakab L, Messina D
• Available for online viewing during program

Role of Bacteria on the In Vitro Immune Response to Hyaluronic Acid Fillers

• Authors: Hee C, Messina D
• Available for online viewing during program

Differential Facial Aesthetic Treatment Considerations for Skin of Color Populations: African American, Asian, and Hispanic

• Authors: Boyd C, Chiu A, Montes JR, Narurkar V, Shumate G, Gallagher C
• Available for online viewing during program

Maximizing Panfacial Aesthetic Outcomes: Findings and Recommendations From the HARMONY Study

• Authors: Kaminer M, Cohen J, Narurkar V, Shamban A, Werschler P, Shumate G, Gallagher C
• Available for online viewing during program

Long-term Topical Oxymetazoline Hydrochloride 1.0% Demonstrates Sustained and Increasing Effect in Persistent Facial Erythema of Rosacea

• Authors: Gold M, Lebwohl M, Biesman B, Robinson E, Fu Y, Berk D, Ahluwalia G, Alvandi N
• Available for online viewing during program

Improvements in Submental Fat Achieved With ATX-101 (Deoxycholic Acid Injection) Are Maintained Over Time: 3-Year Follow-up Data From the Phase 3 REFINE Trials

• Authors: Humphrey S, Bhatia A, Green L, Cohen J, Green J, Liu C, Somogyi C
• Available for online viewing during program

ATX-101 (Deoxycholic Acid Injection) Leads to Clinically Meaningful Improvement in Submental Fat: Final Data From CONTOUR

• Authors: Beer K, Callender V, Fagien S, Munavalli G, Fabi S, Sadick N, Orejudos A, Gallagher C
• Available for online viewing during program

About Allergan plc

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model ? Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceutical, device, biologic, surgical and regenerative medicine products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology and anti-infective therapeutic categories.

Allergan is an industry leader in Open Science, a model of research and development, which defines our approach to identifying and developing game-changing ideas and innovation for better patient care. With this approach, Allergan has built one of the broadest development pipelines in the pharmaceutical industry.

Allergan's success is powered by our global colleagues' commitment to being Bold for Life. Together, we build bridges, power ideas, act fast and drive results for our customers and patients around the world by always doing what is right.

With commercial operations in approximately 100 countries, Allergan is committed to working with physicians, healthcare providers and patients to deliver innovative and meaningful treatments that help people around the world live longer, healthier lives every day.

For more information, visit Allergan's website at www.Allergan.com.

Forward-Looking Statement

Statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Allergan's current perspective on existing trends and information as of the date of this release. Actual results may differ materially from Allergan's current expectations depending upon a number of factors affecting Allergan's business. These factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS^®, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017. Except as expressly required by law, Allergan disclaims any intent or obligation to update these forward-looking statements.

SOURCE Allergan plc